Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

March 25, 2010 09:25 ET

Global Health to Close $4,200,000 Financing With Private Investment Fund

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 25, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) is pleased to announce that it has signed an agreement with a Chicago, Illinois based investment fund (the "Investor"), a private limited partnership organized in Illinois, for a convertible debenture in the principal amount of $4,200,000. The debenture, which has a maturity of 48 months unless called earlier by either party, bears interest at 6% per annum. The Investor also has been granted Warrants for 800,000 shares of the Company at a pre-determined price of $1. The Investor has been granted the right of first refusal with respect to future financings."

"We are very pleased with this investment, and are confident that these new funds shall help the company to reach its goals", said Dr. Hassan Salari, President & CEO of Global Health Ventures Inc.

About Global Health Ventures

Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. X-Excite is presently in clinical trials in Europe.

Notice Regarding Forward Looking Statements

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products... Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information